Where Will Bitcoin Be in 10 Years?
Investors are surely wondering what the future holds. Where will Bitcoin be in 10 years?
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue »
Bitcoin's scarcity
Bitcoin has been around for about 16 years. It has stood the test of time despite numerous price declines of more than 50%. There have been crypto exchange failures and investors have lost their coins. But it's worth mentioning that the Bitcoin network itself has never been hacked.
That durability is a positive factor that should give investors confidence. The longer Bitcoin stays relevant, the lower the chance that it falls by the wayside.
And over time, a higher number of market participants, whether that's individuals, institutions, or politicians, are learning about what makes Bitcoin truly special, which is its fixed supply of 21 million coins. This is in stark contrast to the ever-increasing amount of fiat currency there is in the world. The growth of the money supply in the U.S., as well as federal debt, is showing no signs of slowing down.
This makes the value proposition of owning a purely digital, decentralized, and scarce asset strikingly clear.
Bitcoin's network effect
The great Warren Buffett once called Bitcoin "rat poison squared." His view is understandable, as the cryptocurrency doesn't generate revenue and cash flows like a typical business does, which is what Buffett wants to see. But the Oracle of Omaha appreciates companies that possess economic moats. Applying that same framework to Bitcoin would make anyone bullish.
Its current market cap dwarfs any other blockchain, now at $2.1 trillion. Being the oldest and most valuable cryptocurrency means that Bitcoin has an unrivaled network effect. More users make Bitcoin more valuable to all other stakeholders. Unless a cryptocurrency is magnitudes better than Bitcoin at being a decentralized and secure store of value, there is minimal risk that a newcomer will topple it.
Bitcoin's clear network effect benefits it in another very important way, which is the development of various tools that support its adoption. This includes hardware wallets, mining equipment, and an expanding ecosystem of financial services.
All of this shows that Bitcoin's network effect has supported its rise up to this point. This key competitive advantage increases the chances that this digital asset will not only survive but thrive over the next decade and beyond.
Bitcoin's 10-year price target
I think it's always a good idea for investors to take analyst stock price targets with a grain of salt. The same is true with cryptocurrencies. That's because the future is unpredictable, and humans are terrible at making accurate predictions.
However, that doesn't mean assessing what Bitcoin could be worth by 2035 is a waste of time. I actually think it's a valuable exercise to figure out what things could look like, just so investors have an idea of what the upside could be. Just don't expect Bitcoin to generate the same return during the next 10 years that it did in the past decade.
As of this writing, Bitcoin trades at about $106,000, not that far off of its record high. It might seem like a bad time to put money to work near a peak. But consider that gold, which is arguably Bitcoin's most direct competitor as a global store of value, has a market value of $22.1 trillion. As the world becomes increasingly digital, I don't believe it's a stretch for Bitcoin to one day exceed the precious metal.
Of course, it's anyone's guess as to the ultimate time frame for that happening. If Bitcoin has more than 10-fold upside from today's level, then it seems like a smart investment to make with a 10-year outlook.
Should you invest $1,000 in Bitcoin right now?
Before you buy stock in Bitcoin, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Bitcoin wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $638,985!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $853,108!*
Now, it's worth noting Stock Advisor 's total average return is978% — a market-crushing outperformance compared to171%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor.
See the 10 stocks »
*Stock Advisor returns as of May 19, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
13 minutes ago
- Globe and Mail
U.S. Department of Justice to Sponsor Cellebrite for FedRAMP ATO
TYSONS CORNER, Va., July 23, 2025 (GLOBE NEWSWIRE) -- Cellebrite (NASDAQ: CLBT), a global leader in premier Digital Investigative solutions for the public and private sectors, today announced the U.S. Department of Justice (DOJ) will serve as the official sponsoring agency for the platform's pursuit of a FedRAMP High authorization. Cellebrite announced its intent to pursue FedRAMP authorization in 2024. In 2025, Cellebrite Government Cloud (CGC) was reviewed by a Third-Party Assessment Organization (3PAO), and the FedRAMP Program Management Office (PMO) prepared a Readiness Assessment Report (RAR), which granted Cellebrite Government Cloud FedRAMP High Ready status. DOJ's sponsorship is the critical step required for Cellebrite Government Cloud (CGC) to advance from its current FedRAMP High Ready designation to 'In Process' status. This marks a major milestone that significantly accelerates Cellebrite's compliance journey towards a full Authorization to Operate (ATO). 'We are proud to offer our U.S. federal customers reliable, secure and cutting-edge cloud solutions that enhance their investigative processes and expedite their missions,' said Erik Sachwitz, General Manager of Cellebrite Federal Solutions, Inc. 'We are grateful to the Justice Department for entrusting us to implement their workflow on the Cellebrite Government Cloud. This milestone marks a significant advancement to our ongoing efforts to deepen our support of U.S. federal agencies.' The Cellebrite Government Cloud (CGC) will launch with a comprehensive suite of digital investigative tools. The initial offering provides U.S. federal agencies secure access to two of the company's market-leading solutions: Cellebrite Inseyets, enabling immediate online access to Cellebrite's latest digital forensics capabilities, and Cellebrite Guardian, for collaborative digital evidence review, sharing and storage. Together, these integrated solutions are designed to deliver greater operational efficiencies, support end-to-end collaboration and strengthen the overall chain of custody to help U.S. federal agencies advance their missions while meeting the scalability and security requirements of national, regional and local public safety customers. By shifting digital investigation workflows to the cloud, agencies and attorneys gain secure, flexible access to evidence from anywhere, while also harnessing advanced analytical capabilities enabled by powerful cloud infrastructure. Demonstrating a commitment to supporting diverse missions and operational environments, Cellebrite ensures agencies will continue to have access to on-premises, hybrid and fully offline solutions, empowering them to operate effectively regardless of their unique requirements. References to Websites and Social Media Platforms References to information included on, or accessible through, websites and social media platforms do not constitute incorporation by reference of the information contained at or available through such websites or social media platforms, and you should not consider such information to be part of this press release. About Cellebrite Cellebrite's (Nasdaq: CLBT) mission is to enable its global customers to protect and save lives by enhancing digital investigations and intelligence gathering to accelerate justice in communities around the world. Cellebrite's AI-powered Digital Investigation Platform enables customers to lawfully access, collect, analyze and share digital evidence in legally sanctioned investigations while preserving data privacy. Thousands of public safety organizations, intelligence agencies, and businesses rely on Cellebrite's digital forensic and investigative solutions—available via cloud, on-premises, and hybrid deployments—to close cases faster and safeguard communities. To learn more, visit us at and find us on social media @Cellebrite. Caution Regarding Forward Looking Statements This document includes 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the United States Private Securities Litigation Reform Act of 1995. Forward looking statements may be identified by the use of words such as 'forecast,' 'intend,' 'seek,' 'target,' 'anticipate,' 'will,' 'appear,' 'approximate,' 'foresee,' 'might,' 'possible,' 'potential,' 'believe,' 'could,' 'predict,' 'should,' 'could,' 'continue,' 'expect,' 'estimate,' 'may,' 'plan,' 'outlook,' 'future' and 'project' and other similar expressions that predict, project or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include, but are not limited to, this marks a major milestone that significantly accelerates Cellebrite's compliance journey towards a full Authorization to Operate (ATO); and we are proud to offer our U.S. federal customers reliable, secure and cutting-edge cloud solutions that enhance their investigative processes and expedite their missions are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to: Cellebrite's ability to continue advancing its FedRAMP activities to achieve full FedRAMP authorization in a timely manner; Cellebrite's ability to keep pace with technological advances and evolving industry standards; Cellebrite's material dependence on the purchase, acceptance and use of its solutions by law enforcement and government agencies; real or perceived errors, failures, defects or bugs in Cellebrite's DI solutions; Cellebrite's failure to maintain the productivity of sales and marketing personnel, including relating to hiring, integrating and retaining personnel; intense competition in all of Cellebrite's markets; the inadvertent or deliberate misuse of Cellebrite's solutions; failure to manage its growth effectively; Cellebrite's ability to introduce new solutions and add-ons; Cellebrite's dependency on its customers renewing their subscriptions and purchasing new subscriptions; the low volume of business Cellebrite conducts via e-commerce; risks associated with the use of artificial intelligence; the risk of requiring additional capital to support the growth of its business; risks associated with Cellebrite's dependency on third parties for supplying components or services and with higher costs or unavailability of materials used to create its hardware product components; fluctuations in foreign currency exchange rates; lengthy sales cycle for some of Cellebrite's solutions; near term declines in new or renewed agreements; risks associated with inability to recruit, train and retain qualified personnel and senior management; the security of Cellebrite's operations and the integrity of its software solutions against cyber-attacks, information technology system breaches or disruptions; risks associated with the negative publicity related to Cellebrite's business and use of its products; risks related to Cellebrite's intellectual property; the regulatory constraints to which Cellebrite is subject; risks associated with Cellebrite's operations in Israel, including the ongoing Israel-Hamas war, the increased tension between Israel and Iran and its proxies, including the ongoing hostilities between Israel and Hezbollah, and the risk of a greater regional conflict; risks associated with different corporate governance requirements applicable to Israeli companies and risks associated with being a foreign private issuer and an emerging growth company; market volatility in the price of Cellebrite's shares; changing tax laws and regulations; risks associated with joint, ventures, partnerships and strategic initiatives; risks associated with Cellebrite's significant international operations, including due to fluctuations in foreign currency exchange rates, rising global inflation and exposure to regions subject to political or economic instability; risks associated with Cellebrite's failure to comply with anti-corruption, trade compliance, anti-money-laundering and economic sanctions laws and regulations; risks relating to the adequacy of Cellebrite's existing systems, processes, policies, procedures, internal controls and personnel for Cellebrite's current and future operations and reporting needs; and other factors, risks and uncertainties set forth in the section titled 'Risk Factors' in Cellebrite's annual report on Form 20-F filed with the SEC on March 18, 2025, and in other documents filed by Cellebrite with the U.S. Securities and Exchange Commission ('SEC'), which are available free of charge at You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made, in this communication or elsewhere. Cellebrite undertakes no obligation to update its forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by securities and other applicable laws. Media Victor Cooper Sr. Director of Corporate Communications + Content Operations +1 404.510.2823 Investor Relations Andrew Kramer Vice President, Investor Relations investors@ +1 973.206.7760
National Post
13 minutes ago
- National Post
Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series
Article content Article content CAMBRIDGE, Mass. — Enveric Biosciences (NASDAQ: ENVB) ('Enveric' or the 'Company'), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced a second Notice of Allowance from the United States Patent and Trademark Office (USPTO) for novel compounds within its EVM401 Series, expanding its intellectual property assets in the treatment of mental health disorders. Article content The allowed patent application, titled 'Substituted N-Propylamine Fused Heterocyclic Mescaline Derivatives,' covers a unique series of methylone-inspired compounds, which are structurally differentiated benzodioxole derivatives engineered as non-hallucinogenic modulators of neurotransmitters relevant for neuropsychiatric disorders. Article content 'With this second patent allowance for the EVM401 Series, Enveric continues to strengthen its position as a first-in-class developer of neuroplastogenic small-molecule therapeutics,' said Joseph Tucker, Ph.D., Director and CEO of Enveric. 'These patent-protected molecules are designed to capture the desirable neuroplasticity-promoting effects of methylone, while offering novel chemical structures that enable both strong IP protection and a potential path to repeat-dose outpatient care.' Article content Enveric's molecules share pharmacophoric elements with methylone, an MDMA analog recently associated with positive Phase 2 results for post-traumatic stress disorder (PTSD), but differ structurally in ways that render them patentable and proprietary. In contrast, methylone, a synthetic cathinone with structural limitations, has no available composition of matter patent exclusivity because its structure is in the public domain. Article content Enveric's differentiated benzodioxole analogs may offer similar therapeutic promise while potentially enabling a clearer regulatory and commercial path. The Company expects further preclinical testing will be required to evaluate safety, pharmacokinetics, and functional activity against PTSD and other psychiatric endpoints. Article content 'The expansion of the EVM401 Series reflects Enveric's commitment to developing a deep pipeline of next-generation, non-hallucinogenic neuroplastogens that align with the scalability and safety needs of modern mental health treatment,' added Dr. Tucker. 'We believe this patent further positions Enveric at the forefront of the development of a new wave of targeted, accessible neuroplastogenic small-molecule drugs' Article content About Enveric Biosciences Article content Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders. Leveraging its unique discovery and development Psybrary™ platform, which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications, Enveric seeks to develop a robust intellectual property portfolio of novel drug candidates. Enveric's lead molecule, EB-003, is a potential first-in-class neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering from difficult-to-address mental health disorders. Enveric is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing other novel, patented Psybrary™ platform drug candidates to third-party licensees advancing non-competitive market strategies for patient care. Enveric is headquartered in Naples, FL with offices in Cambridge, MA and Calgary, AB Canada. For more information, please visit Article content Forward-Looking Statements Article content This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as 'plans,' 'expects' or 'does not expect,' 'proposes,' 'budgets,' 'explores,' 'schedules,' 'seeks,' 'estimates,' 'forecasts,' 'intends,' 'anticipates' or 'does not anticipate,' or 'believes,' or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize and submit its IND filing to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric's products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively. Article content A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric's filings with the Securities and Exchange Commission, including Enveric's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Article content Article content Article content Article content Contacts
National Post
13 minutes ago
- National Post
Boann Social Impact Contributes $617K to Catalytic Capital Lab's Loan Guarantee Pool
Article content TORONTO — Boann Social Impact is proud to contribute $617,000 to support developing a pan-Canadian loan guarantee pool, designed to diversify risk, attract investment, and strengthen the resilience of Canada's social finance market. Article content Funded through the Government of Canada's Social Finance Fund, Boann's contribution reflects a strategic focus on blended finance tools that lower risk, unlock private capital, and build a stronger social finance ecosystem. 'This is more than a financial commitment – it's an investment in building a diverse, inclusive economy where everyone in Canada can participate and prosper,' says Brian Smith, Managing Director of Engagement and Market Development at Boann. 'Loan guarantees remain an underused but powerful tool to help capital reach people and places often overlooked by traditional finance. We see strong potential for growth and impact.' Article content The Catalytic Capital Lab helps social finance intermediaries (SFIs) in launching and scaling their operations, unlocking more capital, and driving deeper community impact. Over the next two years, Boann's investment is supporting the project team to design, develop, and implement a durable $50 million loan guarantee pool that will back 30-40 community loan providers across Canada. This contribution also funds robust financial modelling, rigorous oversight, risk mitigation strategies, legal structuring, and investor engagement – all key to ensuring long-term sustainability and impact. Article content 'This kind of catalytic support helps de-risk new models and ultimately allows more capital to flow to the communities that need it most,' says Kristi Rivait, Board Chair at Thrive Impact Fund. 'It's exciting to see Boann leaning in to grow the tools and infrastructure that are essential for a more inclusive and resilient social finance market.' Article content Boann joins partners including 10C Shared Space's Harvest Impact Fund, Definity Insurance Foundation, Ontario Trillium Foundation, Scale Institute and Thrive Impact Fund, in advancing access to capital for community organizations across Canada. 'Collaborative approaches like the loan guarantee pool are critical to unlocking capital that meets the needs of local communities,' adds Julia Grady, Principal of Harvest Impact Fund. 'With partners like Boann at the table, we can help community loan providers build their local economy across the country.' Article content Article content Article content Article content Article content Contacts Article content Media Contacts Article content Article content Boann Social Impact Article content Article content Article content Article content Article content Article content
